SCTPF News Alert Trillium Therapeutic (SCTPF) 8.6500 02/15/2015
Post# of 64074
Posted On: 02/15/2015 12:58:35 PM
Trillium Therapeutic (SCTPF) 8.6500 $SCTPF
Stem Cell Therapeutics Markets
PR Newswire - Tue Feb 10, 12:08PM CST
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas.
Trillium Therapeutics to List Common Shares on the NASDAQ Capital Market Under the Symbol TRIL
GlobeNewswire - Thu Dec 18, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium"
(TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its common shares have been approved for listing on the NASDAQ Capital Market under the symbol "TRIL". Trading will commence on or around December 19. The Company will retain its listing on the Toronto Stock Exchange (TSX) under the symbol "TR".
TR.TO: 16.45 (-0.87)
Stem Cell Therapeutics Markets: 2014 Report
PR Newswire - Mon Nov 17, 6:28AM CST
DUBLIN, Nov. 17, 2014 Research and Markets has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Research and Markets: Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
Business Wire - Mon Nov 17, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dwcl2d/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
M2 - Mon Nov 17, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/qqvpmm/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering. There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas. Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach - using both a bottom-up model and comparing data with a top-down analysis - was used to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. New therapeutic applications of stem cells could potentially be realized in all of the following disease segments: - Blood and Blood-Forming Organs - Circulatory System - Endocrine and Metabolic System and Immunity Disorders - Eye - Gastrointestinal System - Musculoskeletal System and Connective Tissue Disorders - Neoplasms - Nervous System - Respiratory System - Skin and Subcutaneous Tissues Key Topics Covered: One: Executive Summary Two: Stem Cells: An Introduction Three: Regulatory Landscape And Research Policy Four: Development Profiles And Analysis Five: Therapeutic Applications: Current And Potential Stem Cell Segments Six: Stem Cell Market Summary And Outlook Appendix: Industry Participants For more information visit http://www.researchandmarkets.com/research/qqvpmm/stem_cell
Trillium Therapeutics Provides Corporate Update and Announces Reverse Stock Split for NASDAQ Listing
GlobeNewswire - Thu Nov 13, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium" (TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following corporate update:
TR.TO: 16.45 (-0.87)
Report: Stem Cell Technologies Market Growing
PR Newswire - Fri Oct 31, 6:13AM CDT
Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. This includes revenues from proprietary stem cell therapeutics that have gained or are expected to gain approval from respected regulatory authorities.
Trillium Therapeutics Expands CD47 Program Into Solid Tumors Through a Broad Academic Collaboration
Marketwire - Thu Aug 07, 6:04AM CDT
Trillium Therapeutics Inc. ("Trillium" (TSX: TR)(OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a collaboration with academic investigators in London, Ontario to explore the therapeutic potential of SIRPaFc, its CD47-blocking agent, in a variety of solid tumor models. The research will be conducted in the laboratories of Drs. James Koropatnick and Ting-Yim Lee, at the Lawson Health Research Institute and the Robarts Research Institute, University of Western Ontario. Trillium's funding will be matched 1:1 by a grant from the Ontario Research Fund - Research Excellence (ORF-RE), providing the collaboration with a robust research budget nearing $600,000.
TR.TO: 16.45 (-0.87)
Trillium Therapeutics Receives Prestigious National Award
Marketwire - Fri Jun 13, 9:01AM CDT
Trillium Therapeutics Inc. ("TTI" (TSX: TR)(OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has been awarded BIOTECanada's 2014 Gold Leaf Award as Early Stage Health Company of the Year.
TR.TO: 16.45 (-0.87)
Stem Cell Therapeutics Markets
PR Newswire - Tue Feb 10, 12:08PM CST
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas.
Trillium Therapeutics to List Common Shares on the NASDAQ Capital Market Under the Symbol TRIL
GlobeNewswire - Thu Dec 18, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium"
(TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its common shares have been approved for listing on the NASDAQ Capital Market under the symbol "TRIL". Trading will commence on or around December 19. The Company will retain its listing on the Toronto Stock Exchange (TSX) under the symbol "TR". TR.TO: 16.45 (-0.87)
Stem Cell Therapeutics Markets: 2014 Report
PR Newswire - Mon Nov 17, 6:28AM CST
DUBLIN, Nov. 17, 2014 Research and Markets has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Research and Markets: Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
Business Wire - Mon Nov 17, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dwcl2d/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
M2 - Mon Nov 17, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/qqvpmm/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering. There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas. Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach - using both a bottom-up model and comparing data with a top-down analysis - was used to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. New therapeutic applications of stem cells could potentially be realized in all of the following disease segments: - Blood and Blood-Forming Organs - Circulatory System - Endocrine and Metabolic System and Immunity Disorders - Eye - Gastrointestinal System - Musculoskeletal System and Connective Tissue Disorders - Neoplasms - Nervous System - Respiratory System - Skin and Subcutaneous Tissues Key Topics Covered: One: Executive Summary Two: Stem Cells: An Introduction Three: Regulatory Landscape And Research Policy Four: Development Profiles And Analysis Five: Therapeutic Applications: Current And Potential Stem Cell Segments Six: Stem Cell Market Summary And Outlook Appendix: Industry Participants For more information visit http://www.researchandmarkets.com/research/qqvpmm/stem_cell
Trillium Therapeutics Provides Corporate Update and Announces Reverse Stock Split for NASDAQ Listing
GlobeNewswire - Thu Nov 13, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium"
(TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following corporate update: TR.TO: 16.45 (-0.87)
Report: Stem Cell Technologies Market Growing
PR Newswire - Fri Oct 31, 6:13AM CDT
Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. This includes revenues from proprietary stem cell therapeutics that have gained or are expected to gain approval from respected regulatory authorities.
Trillium Therapeutics Expands CD47 Program Into Solid Tumors Through a Broad Academic Collaboration
Marketwire - Thu Aug 07, 6:04AM CDT
Trillium Therapeutics Inc. ("Trillium"
(TSX: TR)(OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a collaboration with academic investigators in London, Ontario to explore the therapeutic potential of SIRPaFc, its CD47-blocking agent, in a variety of solid tumor models. The research will be conducted in the laboratories of Drs. James Koropatnick and Ting-Yim Lee, at the Lawson Health Research Institute and the Robarts Research Institute, University of Western Ontario. Trillium's funding will be matched 1:1 by a grant from the Ontario Research Fund - Research Excellence (ORF-RE), providing the collaboration with a robust research budget nearing $600,000. TR.TO: 16.45 (-0.87)
Trillium Therapeutics Receives Prestigious National Award
Marketwire - Fri Jun 13, 9:01AM CDT
Trillium Therapeutics Inc. ("TTI"
(TSX: TR)(OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has been awarded BIOTECanada's 2014 Gold Leaf Award as Early Stage Health Company of the Year. TR.TO: 16.45 (-0.87)
(0)
(0)Scroll down for more posts ▼